A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs Zatolmilast (Primary)
- Indications Neurodevelopmental disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shionogi
- 04 Feb 2025 According to a Shionogi & Co media release, Jordan's Guardian Angels and Shionogi announced a research collaboration between their organizations and the first-ever clinical trial evaluating an investigational drug for PPP2 syndrome (Jordan's Syndrome).
- 04 Feb 2025 According to a Shionogi & Co media release, Phase 2 study of zatolmilast in Jordan's Syndrome will enroll 30 participants in early 2025. The study is expected to conclude in late 2026.
- 11 Dec 2024 New trial record